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Identification of candidate genes 
for devil facial tumour disease 
tumourigenesis
Robyn L. Taylor1, Yiru Zhang2, Jennifer P. Schöning2,4 & Janine E. Deakin  3
Devil facial tumour (DFT) disease, a transmissible cancer where the infectious agent is the tumour itself, 
has caused a dramatic decrease in Tasmanian devil numbers in the wild. The purpose of this study was 
to take a candidate gene/pathway approach to identify potentially perturbed genes or pathways in 
DFT. A fusion of chromosome 1 and X is posited as the initial event leading to the development of DFT, 
with the rearranged chromosome 1 material now stably maintained as the tumour spreads through 
the population. This hypothesis makes chromosome 1 a prime chromosome on which to search for 
mutations involved in tumourigenesis. As DFT1 has a Schwann cell origin, we selected genes commonly 
implicated in tumour pathways in human nerve cancers, or cancers more generally, to determine 
whether they were rearranged in DFT1, and mapped them using molecular cytogenetics. Many cancer-
related genes were rearranged, such as the region containing the tumour suppressor NF2 and a copy 
gain for ERBB3, a member of the epidermal growth factor receptor family of receptor tyrosine kinases 
implicated in proliferation and invasion of tumours in humans. Our mapping results have provided 
strong candidates not previously detected by sequencing DFT1 genomes.
Tasmanian devils (Sarcophilus harrisii) are the world’s largest marsupial carnivores endemic to the island state of 
Tasmania, Australia. Wild Tasmanian devil populations have been succumbing to a clonal metastatic transmissi-
ble cancer known as Devil Facial Tumour Disease (DFTD), which was first noticed in the mid 1990s in the North 
East corner of the state and has since spread rapidly across the wild devil population range of the island, dramati-
cally reducing Tasmanian devil numbers and causing devils to be listed as an endangered species in 20091, 2.
DFTD is a soft tissue neoplasm of Schwann cell origin3, 4, often appearing within oral cavities and around the 
jowls2, 5 that, so far, has no known pathogenic etiology or transmission route. DFTD is most likely transmitted 
allogeneically where free live tumour cells metastasise from affected individuals to healthy individuals through 
intimate contact such as biting, which is a social behaviour in groups of devils6–9. It has been shown that the DFT 
cells are not recognised by the devil immune system as ‘non-self ’ and evasion of the immune system allows free 
live tumour cells to grow rapidly and metastasise10, 11.
Allogeneic transmission of clonal tumour cells, cells originating in one individual and continue passaging 
throughout different individuals and populations, accumulating genetic mutations over time, was suggested as 
the method of transmission following the observation that the karyotype of devil facial tumour (DFT) cells from 
different individuals were the same6, 12. The chromosomes from DFT cells were highly rearranged, with both 
copies of chromosome 1 and X and one copy of chromosome 5 rearranged to form distinctive marker chromo-
somes13 (Fig. 1). Genotyping of microsatellites, single nucleotide polymorphisms (SNPs) and major histocompat-
ibility complex (MHC) alleles as well as mitochondrial DNA sequencing have supported this theory of allogenic 
transmission, demonstrating that tumour genotypes did not match those of the their host and genotypes of 
tumours from different individuals were identical or near identical to each other3, 14–16. A second, independently 
derived, transmissible tumour (DFT2) causing DFTD has been recently described in animals from the south east 
of Tasmania but it has a very different karyotype to the first tumour (DFT1) and most likely a different cellular 
origin17.
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DFT1 is proposed to have arisen from telomeres on one homologue of chromosomes 1 and X becoming 
critically short, permitting the fusion of these two chromosomes, followed by a series of breakage-fusion-bridge 
cycles to ultimately result in their shattered appearance in the DFT1 karyotype13, 18. The transmissible tumour is 
evolving as it as spreads through the devil population, accumulating mutations resulting in visible, karyotypic 
differences12. Four different karyotypes have been classified based on G-banding and are referred to as Strains 1 
to 4 of DFT1. Strains 1 and 2 are the most common strains detected across Tasmania and differ by the presence 
of an additional marker chromosome in Strain 2; Strain 3 is geographically restricted to the Forrestier Peninsula; 
Strain 4, the most derived and potentially more virulent strain, is restricted to eastern Tasmania12. The use of these 
classifications into strains may be misleading as similar magnitude differences have been detected within strains 
as between strains when more sensitive, molecular cytogenetic analyses were performed13. The karyotypic differ-
ences appear mainly in material from chromosomes 3, 4 and 512, 13 (Fig. 1) but the arrangement of chromosome 
1 material in the tumour is stable, suggesting that this arrangement is required for the survival of the tumour13.
Mutations driving tumourigenesis in DFTD are yet to be identified. The emergence of a second transmissible 
tumour makes it imperative that we gain a better understanding of DFT tumourigenesis. It is challenging to deter-
mine mutations contributing to tumorigenesis in human cancers, where there is access to matched tumour and 
host samples and extensive resources, including a well-assembled and annotated human reference genome19. In 
DFTD, extra layers of difficulty exist for determining genes involved in tumourigenesis. Transcriptome sequenc-
ing has determined a Schwann cell origin of DFT13, but identifying genes aberrantly expressed in the tumour is 
limited by the lack of a Schwann cell control to compare with DFT1 expression. Attempts to isolate and estab-
lish devil Schwann cell cultures have proven challenging (R. Taylor, unpublished). Moreover, two independ-
ent genome projects have sequenced devil and DFT1 genomes, and have only detected a very small number of 
sequence mutations in genes that could potentially contribute to DFT1 tumourigenesis but no obvious driver 
candidates15, 16. Furthermore, the lack of a sample from the founder animal in which the tumour initially arose 
leaves some doubt as to whether sequence differences are mutations that may affect gene function or merely poly-
morphisms between different individuals. Considering the complex chromosome rearrangements in DFT113 and 
the known role chromosome rearrangements can play in tumorigenesis in human cancers20, structural mutations 
may play a prominent role in DFT1 tumourigenesis. Unfortunately, the current reference devil genome assembly 
is fragmented (over 35,000 scaffolds), making it challenging to reliably detect rearrangements, although some 
rearrangements have been detected and validated15.
As an alternative approach, we have exploited our understanding of the structural changes and the Schwann 
cell origin of the tumour to predict prime candidate genes that may be affected in DFT1, in order to identify 
potentially perturbed pathways for further investigation. The fusion of chromosome 1 and X is predicted to be 
the event leading to tumourigenesis in DFT113, 18, making the large chromosome 1 a logical place to start a search 
for potential driver mutations, with strong candidate genes being those involved in tumourigenesis in peripheral 
nerve sheath tumours in humans. Firstly, we decided to test the stability of this chromosome through further 
mapping of bacterial artificial chromosome (BAC) clones on DFT1 chromosomes from three different samples 
for which there is already mapping data available13. Secondly, we selected cancer-related genes located on the 
other autosomes. We predicted that genes located on devil chromosome 1 and 5 would be rearranged in DFT1 as 
these chromosomes are highly rearranged in the tumour, and genes on devil chromosomes 2 and 6 would not be 
perturbed as these chromosomes have few rearrangements13. Some regions of chromosome 4 are rearranged in 
DFT113, so we predicted that it was possible that at least some of the cancer-related genes we selected from this 
chromosome would be rearranged in the tumour. Our approach has given further support for the stable nature of 
chromosome 1 material in DFT1 and provided a means for selecting genes and pathways for further analysis for 
their role in DFT1 tumourigenesis.
Figure 1. The normal devil karyotype consists of 6 pairs of autosomes and a pair of sex chromosomes. In DFT1, 
chromosome 1 and X material is spread across up to 5 marker chromosomes (M1-M5) (colour-coded to show 
their homology to devil chromosomes). Chromosomes varying between and within DFT1 strains are indicated 
by an asterisk, including the presence or absence of double minutes (DM). The karyotype has been arranged 
according to the original devil and standard dasyurid karyotypes46, differing from the karyotype presented by 
Pearse and Swift6 in the order of chromosomes 1 and 2.
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Results
We tested our hypothesis that the rearranged chromosome 1 material in DFT1 is stable and therefore, a likely 
chromosome to harbour mutations driving DFT1 tumourigenesis. We generated a dense map of devil chro-
mosome 1 by mapping an additional 29 BACs to devil chromosome 1 and three DFT1 samples, with distinct 
karyotypic differences13 and from different geographic locations (Supplementary Figure S1). Then, we mapped 
22 cancer-related genes to chromosome 1 and other autosomes to identify potentially perturbed genes/pathways 
in DFT1.
Dense cytogenetic map of chromosome 1 BACs on normal and DFT1 chromosomes. The devil 
genome project, which sequenced flow sorted chromosomes, allowed genes to be assigned to normal devil chro-
mosomes but their precise location on the chromosome was unknown15. We isolated BAC clones for mapping 
corresponding to genes previously mapped to tammar wallaby chromosomes21 (to permit a direct comparison of 
gene arrangement between marsupials if needed), or the ends of large (>3 Mbp) sequence scaffolds in the devil 
genome assembly (version 7.0). The genome coordinates of most BAC clones within the devil genome assembly 
were determined by sequencing the ends of each BAC clone (Supplementary Dataset 1A). The position of the 29 
devil BAC clones on devil metaphase chromosomes was incorporated into the previous version of the cytogenetic 
map for chromosome 113 by a combination of ordering genes on the chromosome based on Flpter (fractional 
length p arm terminus) values22 and further refined with two-colour FISH experiments for genes mapping to 
similar locations, resulting in a map consisting of 53 BAC clones distributed across the chromosome (Fig. 2).
We then used DFT1 samples that had been used previously to construct the original cytogenetic map of the 
DFT1 tumours13 and compared gene locations between devil chromosome 1 and all three geographically isolated 
tumours (Supplementary Figure S1). We detected no differences in the location of BACs between three different 
samples (Supplementary Dataset 1B). A comparison of the gene arrangement on devil chromosome 1 versus the 
combined data for the DFT1 arrangement demonstrates the highly rearranged nature of chromosome 1 DNA 
on marker chromosome 1 (M1) (Fig. 3). The other copy of chromosome 1 appears to have essentially split at the 
centromere (with only a few exceptions), with 1p material located on M3 and 1q DNA on M2.
Mapping cancer-related genes in DFT1. We selected genes commonly implicated in tumour pathways 
in human malignant peripheral nerve sheath tumours (MPNSTs) or schwannomas (tumours of Schwann cells), 
as well as some genes often generally perturbed in human cancers, to determine if they were rearranged in DFT1 
and therefore, candidates for contributing to DFT1 tumourigenesis (Table 1; Supplementary Dataset 1C). Based 
on previous molecular cytogenetic characterisation of devil and DFT1 genomes13, and genome sequence infor-
mation15, we were able to predict which genes were most likely to be rearranged in devil facial tumours and those 
unlikely to be affected by structural mutations. Our mapping data confirmed the chromosome assignment given 
in the genome assembly, localised candidate genes to specific sites on devil and DFT1 chromosomes and allowed 
us to test our predictions concerning the genes likely to be rearranged in DFT1. BACs were mapped to at least 
two DFT1 samples.
As predicted, genes located on chromosomes 1 and 5 were predominantly located on the rearranged deriva-
tive chromosomes (Table 1). One stand-out candidate gene identified to be on chromosome 1 from sequencing 
of flow sorted chromosomes15 was NF2, a tumour suppressor gene located on human chromosome 22q12.2. 
NF2 has been implicated in a diverse range of nervous system tumours, including those with a Schwann cell ori-
gin23. Attempts to isolate BAC clones for this gene failed, despite multiple attempts with different overgo probes24 
and two different devil BAC libraries, suggesting that this gene is not represented in either of the BAC librar-
ies. However, we mapped two other BACs from the human 22q region, containing genes THAP7 and LZTR1 
(VMRC49_433C15) and PES1 (VMRC49_253L6). OSBP2, also from this region, was previously mapped to distal 
1q13. We aligned the devil scaffolds to a 10 Mbp region of the opossum genome (the marsupial genome currently 
with the most contiguous assembly across this region) encompassing the NF2 gene. BAC end sequence data 
joins some of the devil reference genome scaffolds in this region (Fig. 4a). The genes in this region map very 
close together on the distal end of devil 1q (Fig. 3). The NF2 gene is the only gene annotated on the 199,584 bp 
scaffold, GL842060.1. Mapping of the genes corresponding to the 10 Mbp region surrounding opossum NF2 
(THAP7/LZTR1, to PES1/OSBP2) onto DFT1 chromosomes shows that this region has undergone rearrange-
ment in DFT1. One copy of PES1 and OSPB2 are located on the derived chromosome 2. The other copy of PES1 
is located on marker chromosome 2 (M2). THAP7/LZTR1 does not map to either of these chromosomes (Figs 3 
and 4b). Instead, the THAP7/LZTR1-containing BAC is located only on the derivative 6q (i.e. one copy has been 
deleted). OSBP2 has also previously been shown to have experienced a deletion of one copy and to only be present 
on the derivative chromosome 2 in DFT113 (Fig. 3).
All other genes selected from devil chromosome 1 were present in DFT1 in two copies, with some remaining 
in what appears to be a similar genomic context to what they are on devil chromosome 1, despite being located 
on marker chromosomes (Fig. 3). However, two of the four chromosome 5 genes have experienced a copy gain 
in DFT1; ERBB3 is located on the short arm of both copies of chromosome 4, as well as the long arm of M4, and 
GALNT2 is located on the short arm of one homologue of chromosome 4, the short arm of chromosome 5 and 
the short arm of M2 (Fig. 5).
We predicted genes on chromosome 4 would possibly be rearranged in DFT1. All six genes selected from this 
chromosome were located in the same positions on chromosome 4 in DFT1 as they are on normal devil chro-
mosomes. However, three of these genes, including the “guardian of the genome” TP53, NGF and KCNH6, had 
at least one addition copy located on another chromosome (Fig. 5), although TP53 only had additional copies 
in one sample (06.2109) tested (Fig. 6). Several attempts to isolate a BAC clone containing devil NF1 using two 
different BAC library filters and different overgo probes failed, suggesting that it may not be represented in either 
of the two available devil BAC libraries (VMRC-49 and VMRC-50)25. However, we were able to isolate a BAC 
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clone corresponding to the genome scaffold containing the NF1 gene, which demonstrated that this region of the 
genome has also experienced a copy gain in DFT1 (Fig. 5).
Cancer-related genes from chromosomes 2 and 6 were also mapped to test our prediction that these were 
unlikely to be rearranged in DFT1. This prediction was correct for three chromosome 2 genes, which each 
mapped to the same location on chromosome 2 on normal devil and DFT1 chromosomes from most samples. 
The one exception was DICER1, which localised to two locations on chromosome 2 in sample 11.3178 and was 
Figure 2. (a) Map of normal devil chromosome 1, including genes from the first generation map13 shown to the 
left of the chromosome, genes mapped as part of this study and large sequence scaffolds (blue) are shown on the 
right of the chromosome. Vertical lines indicate the Flpter value (±1 standard deviation). Shading on the devil 
chromosome corresponds to DAPI banding. (b–e) Examples of FISH results for genes mapping close together 
on chromosome 1. Scale bars represent 10 μm.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 8761  | DOI:10.1038/s41598-017-08908-9
amplified on double minutes (Fig. 6). Contrary to our prediction, EGF, the only gene mapped from devil chromo-
some 6, was not located on chromosome 6 but both copies mapped to chromosome 2 (Fig. 5).
Discussion
It is challenging to determine mutations contributing to pathogenesis in human cancers, where there is access to 
extensive reference resources19. In DFT1, extra layers of difficulty exist for identifying mutations driving tumour-
igenesis. Considering the complex chromosome rearrangements in DFT1, structural mutations play a significant 
role in DFT1 pathogenesis but the current state of the devil reference genome assembly make the accurate identi-
fication of structural mutations challenging based solely on sequence data. By employing a molecular cytogenetic 
approach to target candidate genes, we have detected strong candidates for further investigation for a role in 
Figure 3. Comparison of consensus mapping data from three DFT1 strains with the location of genes on devil 
chromosome 1. Lines indicate the location of the genes on the normal devil chromosome 1 (DAPI banded 
chromosome indicated in the centre) compared to their location on DFT1 chromosomes. Regions of DFT1 
chromosomes and lines indicating position of genes have been colour-coded red for devil 1p genes and blue for 
devil 1q genes. Regions containing genes from both chromosome 1 arms are indicated in pink. Genes mapped 
as part of this study are indicated in colour. Genes mapped previously13 are in black.
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DFT1 pathogenesis. Of the 22 genes selected for mapping, those of particular interest for further investigation 
are those in a very different genomic context (e.g. located on a different chromosome) compared to the normal 
arrangement and/or show a change in copy number in the tumour common to all strains (Table 1).
The event leading to DFT1 tumourigenesis is proposed to be the fusion of chromosome 1 with an X chromo-
some, which led to a series of breakage-fusion-bridge cycles and extensive rearrangement of chromosome 1 mate-
rial on M113, 18. With this idea in mind, along with the now seemingly stable nature of the extensively rearranged 
chromosome 1 material in DFT1, chromosome 1 is a likely source for DFT1 driver mutations. Although many 
genes have been implicated with cancer, we chose candidates based on their known association with nerve cell 
neoplasms or being commonly involved in cancers more generally. The strongest candidate on devil chromosome 
1 is NF2. This hypothesis is based on the frequency of breakpoints in the region encompassing NF2 in humans 
(corresponding to 22q11-13) involved in MPNSTs26, 27, and the role of the loss or inactivation of NF2 in Schwann 
cell tumours28. Although we were unable to isolate and map the NF2 gene as part of this study, we demonstrated 
that this region of the DFT1 genome has undergone rearrangement and even some deletion, including the dele-
tion of one copy of the tumour suppressor LZTR129 (Fig. 4b).
The additional mapping of chromosome 1 genes on devil and DFT1 chromosomes enabled a scenario for 
the initial chromosome rearrangements contributing to DFT1 tumourigenesis to be proposed (Fig. 7). Previous 
research has suggested the loss of telomeres led to the fusion of chromosomes 1 and X13, 18. Our mapping data 
suggest the initial fusion most likely occurred close to the NF2 region at the distal end of 1q and the distal end of 
Xq. Therefore, the NF2 region would have been close to the original site of genome instability and a site of further 
instability, with this region being separated from the rest of chromosome (translocated to chromosome 2 and 6). 
The other copy of this region, located on chromosome M2 has also experienced rearrangement and even deletion 
(OSBP2, THAP7/LZTR1).
NF2 is a tumour suppressor involved in regulating intracellular signalling pathways and cell cycle progres-
sion30. In schwannoma cells lacking NF2, epidermal growth factor receptor tyrosine kinases ErbB2, ErbB3 and 
EFGR are overabundant on the cell surface, upregulating their downstream targets, thereby driving cell pro-
liferation31–33. This is particularly interesting in light of the mapping of ERBB3 in DFT1. ERBB3 is in a very 
different genomic context in the tumour (located on chromosome 4 rather than 5) and has experienced a copy 
number gain (Fig. 5). Consistent with the Schwann cell origin of DFT13, it is therefore not surprising to find 
Gene Role in Schwannomas/MPNSTs
Devil 
Chromosomal 
location DFT1 Chromosomal location
ATRIP Component of DNA damage checkpoint 1p M1q and M3q
EGFR Associated with development of tumours derived from Schwann cells47, 48. 1p M1q and M3q
IGFBP1 Regulates proliferation, adhesion and survival in schwannomas49. 1p M1q and M3q
CDKN2A
Mutated in 50% of MPNSTs, dysregulating p16INK4A cyclinD1-
cyclin-dependent kinase (CDK)4-Retinoblastoma (Rb) and/or p19ARF 
-Mdm2-p53 cell cycle regulatory pathways50–52.
1q M1q and M3q
ICAM1 Involved in tumour growth and metastatis 1q der(2p) and M2q
TERT Telomerase lengthens telomeres in DNA strands (chromosomes) allowing senescent cells to become potentially immortal. 1q M1q and M3p
NF2 Loss of this tumour suppressor is key to the development of most schwannomas28. 1q*
Region rearranged THAP7 end: 
der(6q) PES1 end: der (2p) and M2q
LZTR1 Loss of this tumour suppressor associated with schwannomas35. 1q Rearranged, near breakpoint
DICER1 Involved in microRNA biogenesis with perturbations linked to human cancers53 2p
2p, der(2p) Amplification on double 
minutes in sample 11.3178
IGF1R Frequently amplified in MPNSTs54. 2p 2p, der(2p) (unchanged)
ATMIN Regulates checkpoint kinase ATM55 2q 2p, der(2p) (unchanged)
KCNH6 Expression frequently perturbed in human cancers56 4p 4p, 4p and M4q (copy gain)
NGF Promotes neuronal cell survival and differentiation particularly in Schwann cells57. 4p 4p, 4p and M4q (copy gain)
NRAS Proto-oncogene 4p 4p, 4p and M4q (copy gain)
NF1 A negative regulator of the ras signalling pathway, often mutated in MPNSTs28. 4p* 4p, 4p and M4q (copy gain)
IGF2R Involved in multiple cellular processes dysregulated in tumours58 4q 4q, 4q (unchanged)
TP53 Regulates the cell cycle and is known as the “guardian of the genome” preventing genomic mutations. Mutated in 75% of MPNSTs36, 52. 4q
4q, 4q (unchanged in most samples) 
4q, 4q, M1p, M5p (copy gain in 
sample 06.2109)
ERBB3 A member of the epidermal growth factor receptor family and is over expressed in many cancers including schwannommas and MPNSTs. 5p
4p, 4p, M4q (copy gain and 
rearrangement)
GALNT2 Associated with tumour invasion 5p 4p, 5p, M2p (copy gain and rearrangement)
IGF1 Growth factor 5p 5p, M2p
MDM2 Amplified in a portion of MPNSTs59. 5p 5p, M2p
EGF Promotes cell migration in MPNSTs39. 6p 2p, der(2p) (translocation)
Table 1. Selected cancer-related genes. *NF1 and NF2 were not directly mapped.
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ERBB3 and potentially NF2 the subject of structural mutations. NF2, ErbB3 and downstream effectors PI3K-Akt 
or MAPK signalling pathways are therefore prime candidates for future immunohistochemistry and functional 
studies to determine if they are involved in DFT1 tumourigenesis. It has recently been shown that elevated levels 
of ErbB3 are detectable in devil sera several months prior to visual tumour eruptions34 making it imperative that 
the pathway involving NF2 and ErbB3 be prioritised for further investigation. Additionally, germline mutations 
in the tumour suppressor LZTR1 are associated with a predisposition for an inherited disorder responsible for 
the development of multiple schwannomas in humans35, making the entire NF2 region a high priority for further 
investigation.
TP53 is commonly referred to as “the guardian of the genome” because of its central role as a cell cycle check-
point and tumour suppressor. It is commonly mutated in many cancers, including approximately 75% of human 
MPNSTs, where mutations commonly result in deletion or loss of function of TP5336. It has only experienced a 
copy gain in one of the samples tested (06.2109) (Fig. 6), which is interesting considering most MPNST muta-
tions involve a p53 loss and raises questions as to whether this copy gain affects TP53 function in this strain. 
Transgenic mice with three copies of Trp53 had an enhanced response to DNA damage and an increased resist-
ance to cancer37. It seems likely that TP53 function has been affected in DFT1 since there are four copies of this 
gene. If appropriately regulated, these additional copies should enhance the role of TP53 in tumour suppression. 
However, two of these TP53 copies are in a completely different genomic context, being located on chromosomes 
M1 and M3, and may be aberrantly regulated.
Genome sequencing has previously failed to detect changes in copy number for chromosome 4, making 
the gain in copy number of TP53, the NF1 scaffold, KCNH6 and NGF (Fig. 5) an unexpected finding, whereas 
copy number gains for chromosome 5 had been previously reported15. Among the chromosome 4 genes, 
Neurofibromin 1 (NF1) was the top candidate prior to mapping. NF1 is a tumour suppressor gene, where loss of 
function mutations are associated in humans with the autosomal dominant syndrome Neurofibromatosis type 1. 
Patients with this syndrome often develop MPNSTs, many of which are of Schwann cell origin38. The loss of NF1 
function is seen as an early step in the development of neurofibromas, which then may progress to MPNST with 
mutations in other tumour suppressor genes such as TP53 and CDKN2A28. In this context, a copy gain for the NF1 
region rather than a deletion, make it less likely that NF1 is a driver of DFT1 tumourigenesis. In additional, the 
extra copy of this region is also located on chromosome M4, a highly methylated chromosome compared to other 
DFT1 chromosomes18, which may be an indicator of transcriptional silencing of this chromosome and therefore, 
may not alter the overall gene expression of genes on the NF1 scaffold. The copy number gains observed for NGF 
and KCNH6 also have a low probability of being driver mutations of DFT1 as they are not on a chromosome pos-
ited to be initially involved in the formation of the tumour. They also have two copies of the gene in their normal 
location. Like the NF1 scaffold, the additional copy of KNCH6 is located on chromosome M4. The additional copy 
of NGF is located chromosome M2 and may be aberrantly expressed.
The translocation of EGF (epidermal growth factor) from chromosome 6 to chromosome 2 in DFT1 was 
surprising, as rearrangements involving the movement of genes from chromosome 6 had not been previously 
detected. Finding both copies in the same location on chromosome 2 is intriguing and suggests that this region of 
chromosome 2 may have undergone repair to incorporate EGF on both chromosome 2 homologues. In MPNSTs, 
EGF promotes tumour migration39, making it another candidate for functional analysis.
The amplification of DICER1 on DFT1 double minutes in tumour 11.3178 (Fig. 4) may explain the anecdotal 
evidence that this is a more aggressive lineage (strain 4) of DFT1, killing animals more quickly than other strains 
and resulting in a reduced transmission rate12. DICER1 is a key gene involved in the biogenesis of microRNAs. 
The amplification of this gene may provide an explanation for the faster growth rate observed for strain 4 and its 
Figure 4. The NF2 region (a) Comparison of the 10 Mb region surrounding NF2 on opossum chromosome 3 
(position 510–520 Mb) with devil reference genome scaffolds (each scaffold is a different colour) and human 
chromosomes 22 (blue) and 12 (red). The order of the devil scaffolds is unknown, although BAC end sequences 
join several scaffolds indicated by a dotted line. (b) Rearrangement detected in the NF2 region in DFT1. PES1 is 
located on DFT1 derivative chromosome 2 and M2. Only one signal is detected for THAP7/LZTR1, localising to 
derivative chromosome 6. Scale bar represents 10 μm.
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presumed more aggressive nature12. Changes in the expression levels of DICER1, either an increase or decrease, 
are associated with aggressive human cancers40. In particular, overexpression of DICER1 observed in human 
tumours has been associated with enhanced cell proliferation41 and poor prognosis42. It would be interesting to 
determine whether the amplification of DICER1 correlates with an increase in DICER1 expression and/or deter-
mine the effect of amplification on DICER1 function.
Figure 5. Location of cancer-related genes on devil and DFT1 chromosomes. Genes in grey indicate variations 
observed between samples.
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 8761  | DOI:10.1038/s41598-017-08908-9
Figure 6. (a) TP53 is located on chromosome 4 on normal devil chromosomes and (b) in DFT1 sample 
06.1926. (c) TP53 is located on two additional chromosomes (M1 and M5) in sample DFT1 06.2109. DICER1 
localises to (d) chromosome 2 on normal devil chromosomes. (e) In DFT1 sample 11.3178, DICER1 is 
amplified on double minutes (indicated by arrows). (f) DAPI image to show that green fluorescent signals in (e) 
correspond to double minutes. Scale bars represent 10 μm.
Figure 7. Proposed scenario for the fusion of chromosome 1 and X leading to the formation of marker 
chromosome 1. A loss of telomeres from 1q (adjacent to the NF2 region) permitted the fusion with the X 
chromosome, which had also experienced telomere loss. The resulting dicentric chromosome broke between 
the PHF20L and SHARPIN genes, permitting an inversion of region around the 1q/X fusion. A further break led 
to the region around the original 1q/X fusion containing the NF2 region breaking away from M1. After a break 
permitting the translocation of the fragment containing THOC2 and HEPH to M2, a further inversion around 
the NF2 region brought THAP7 from 1q and ARHGEF6 from Xq together. These genes then translocated to 
derivative chromosome 6 whereas the remaining segment translocated to derivative chromosome 2.
www.nature.com/scientificreports/
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Conclusions
We have confirmed the stable nature of chromosome 1 material in DFT1, supporting the hypothesis that the 
highly rearranged arrangement of chromosome 1 material is required to drive the tumour13. We have also deter-
mined the location of cancer-related genes on DFT1 chromosomes and identified a key genomic region and path-
ways that are potentially perturbed in the tumour, warranting future analysis. This candidate gene approach has 
provided an alternative strategy for identifying genes contributing to DFT1 tumourigenesis in a non-traditional 
model species, with a fragmented reference genome assembly15 and lacking other critical resources. Future 
research into rearrangements in DFT1 would benefit from an improved reference devil genome assembly 
and deep tumour sequencing. Such an improvement to the reference assembly is now within reach given the 
recent advances in sequencing approaches, such as high-throughput conformation capture sequencing, capa-
ble of producing more contiguous genome assemblies from physical contact information43. Comparison of a 
chromosome-level devil reference genome to devil facial tumour genomes would provide details of structural 
mutations at the base pair level and could be particularly powerful if combined with validation of rearrangements 
using molecular cytogenetics. Furthermore, it is imperative that a concerted effort be made to establish devil 
Schwann cell lines, which will be essential for the next steps to determine whether the functions of the prime can-
didate genes and/or regions (e.g. NF2 region, including LZTR1, and ERBB3) are contributing to DFT1 tumour-
igenesis. Future studies are required to determine whether the transcript and/or proteins of genes occurring in 
rearranged regions are perturbed, followed by in vitro experiments on devil Schwann cells and DFT1 cells. There 
will undoubtedly be a suite of genes involved in DFT1 tumourigenesis but those identified here provide a good 
starting place for a more in-depth understanding of the drivers of DFT1.
Methods
BAC library screening. Overgo probes for (i) genes mapped in the tammar wallaby and located near the 
ends of human-opossum evolutionary conserved blocks21, (ii) sequences located near the ends of large sequence 
scaffolds in the devil genome assembly15 or (iii) for genes involved in human cancer. Devil genomic sequence 
for the genes or regions of interest were obtained from Ensembl (genome assembly Devil_ref7.0) and used as 
input sequence for the Overgo Maker program developed by The Genome Institute at Washington University. 
BLASTN searches of the devil genome assembly were performed with the resulting 40 bp overgo probe in order 
to confirm the specificity of all probes. Only probes with a single match across the entire length of the probe were 
used for BAC library screening to avoid hybridization to paralogous sequences. All overgos used for screening are 
listed in Dataset 1. BAC library filters were screened with pools of overgos, radioactively labelled as described by 
Ross et al.24, with dot blots performed on the resulting positive BACs in order to determine the gene each BAC 
contained following the protocol described by Deakin et al.44. In cases where overgos for genes failed to isolate a 
BAC for the target gene, we screened the library with different overgos for a location elsewhere on the sequenced 
genome scaffold.
BACs were end sequenced by Macrogen (Korea) using primers pCC1™/pEpiFOS™ forward sequencing 
primer (5′ GGATGTGCTGCAAGGCGATTAAGTTGG 3′) and pCC1™/pEpiFOS™ reverse sequencing Primer 
(5′ CTCGTATGTTGTGTGGAATTGTGAGC 3′). BAC end sequences were submitted to the GSS database 
(dbGSS Accession KS520996 - KS521086). BAC clones were confirmed to contain the gene of interest by BLASTN 
searching the devil genome assembly (Devil_ref v7.0), using the BAC end sequences as queries.
Fluorescence in situ hybridization (FISH). Devil metaphase chromosomes were prepared from a 
fibroblast cell line using standard methods previously described12. Blood and DFT1 samples were collected 
under approval of the Tasmanian Department of Primary Industries and Water Animal Ethics Committee 
and all methods were performed according to the relevant guidelines and regulations. Metaphase chro-
mosomes were prepared by the Department of Primary Industries, Parks, Water and the Environment as 
previously described12.
DNA was extracted from 15 ml BAC clone cultures using the WIZARD Plus SV Minipreps DNA Purification 
System (Promega, Alexandria, NSW, Australia) using a slightly modified protocol; the volume of all reagents 
added prior to centrifugation to remove cell debris from the lysis process were doubled. Between 500 ng and 1 μg 
of DNA for each BAC was labelled by nick translation with either SpectrumGreen dUTP or SpectrumOrange 
dUTP (Abbott Molecular Inc., Des Plaines, IL, USA) and hybridized to normal devil or DFT chromosomes 
following the method described by Alsop et al.45. Unbound probe was washed off slides, counterstained and 
mounted as described by Deakin et al.13. Chromosomes and BAC signals were visualized and captured using 
either a Zeiss Axioplan2 epifluorescence microscope (Carl Zeiss Ltd, Cambridge, UK) fitted with a SPOT RT3 
Monochrome charge coupled device (CCD) camera (Diagnostic Instruments Inc.) or Zeiss Axiocam MRm Scope 
A1 epifluorescence microscope fitted with an AxioCam Mrm Rev.3 CCD camera (Carl Zeiss Ltd). Measurements 
were taken to determine Flpter values using Adobe Photoshop software.
Data availability. The datasets generated and/or analysed during the current study are available in the 
dbGSS repository (accession KS520996 - KS521086) or are included in this manuscript (and its Supplementary 
Information files).
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